Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Single Ascending Doses of AZD0292 in Healthy Adults
NCT06311760Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2024
- Primary completion
- Feb 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AZD-0292 in bronchiectasis (4 arms), sponsored by AstraZeneca. Primary endpoints: Number of Participants with Adverse Events up to 13 weeks and Number of Participants with Adverse Events of Special Interest up to 13 weeks. Started Apr 2024; status: completed.
02
Drugs
AZD-0292
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT06311760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06311760.